论文部分内容阅读
血清Epstein-Barr病毒脱氧核糖核酸酶抗体(EDAb)检测对鼻咽癌(NPC)早期发现有较高的特异性及灵敏度。由于原检测方法重复性未够理想等原因,目前国际上仍未有一套较完整的EDAb血清学数据。通过进一步研究,作者发现国际上沿用的EDAb滴度单位——酶中和单位/毫升血清随着工作酶用量增加而呈线性上升,而作者首次提出的滴度单位——抗酶率(AER)则在一定酶活性范围内为一常数,其大小决定于被测血清EDAb滴度高低,因而提高检测结果的准确性。以上述技术为基础,作者报告对广东省四会县30～59岁正常人2060例,中山医科大学附属肿瘤医院收集的NPC患者430例,以及其他癌瘤患者204例EDAb检测结果。
Serum Epstein-Barr virus DNAB antibody detection has high specificity and sensitivity for early detection of nasopharyngeal carcinoma (NPC). Due to the lack of ideal reproducibility of the original detection method and other reasons, there is still no complete set of EDAb serological data in the world. Through further research, the authors found that the unit of EDAb used in the world, enzyme neutralization unit/ml serum, rose linearly with the increase of the amount of working enzyme, and the first unit of titer proposed by the author was the enzyme resistance rate (AER). It is a constant within a certain range of enzyme activity, and its size is determined by the serum EDAb titers, thus improving the accuracy of the test results. Based on the above techniques, the authors report 2060 cases of normal people aged 30-59 years in Sihui County, Guangdong Province, 430 NPC patients collected from the Cancer Hospital of Sun Yat-sen University of Medical Sciences, and 204 other cases of cancer patients with EDID.